Market Overview

Eloxx Pharma Says ELX-02 Data Showed Increases In Key Metric


Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.

ELX-02 is focused on the development for cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Cystic fibrosis is caused by the absence or dysfunction of a protein called CFTR that controls the movement of salt and water in an out of cells. ELX-02 has shown increased CFTR function in organoids bearing nonsense alleles representing more than 75 percent of the cystic fibrosis nonsense genotype population.

Eloxx will report top-line data from Phase 2 clinical trial in cystic fibrosis later this year. For now, the Phase 2 protocol has been reviewed and approved by the European Cystic Fibrosis Society-Clinical Trial Network and given a score of “high priority.”

On Thursday afternoon, Eloxx Pharmaceuticals shares traded up 25.7 percent to $11.20.

Related Links:

Insys Therapeutics Board Members Resign After $225M DOJ Settlement

ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

Posted-In: Cystic FibrosisNews Health Care General


Related Articles (ELOX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

What To Know About Alibaba's Russian Joint Venture

Analyst On Cloudera: 'Straw That Broke The Camel's Back'